 incid lymphoprolif disord immunosuppress monoclon antibodi cardiac-transpl recipi background sudden increas incid post-transplant lymphoprolif disord patient cardiac-transplant program introduct immunosuppress drug monoclon antibodi recent year prevent reject cardiac transplant method order variabl develop post-transplant lymphoprolif disord seri consecut cardiac-transpl recipi singl institut univari analys multivari analysi logist regress result patient post-transplant lymphoprolif disord percent patient drug percent incid patient ninefold odd ratio percent confid interv analysi factor develop post-transplant lymphoprolif disord use signific increas risk dose appar patient cumul dose mg percent post-transplant lymphoprolif disord patient mg disord percent conclus addit immunosuppress regimen incid post-transplant lymphoprolif disord cardiac transplant risk increas cumul dose risk benefit prophylact administr light find valu prophylact immunotherapi cardiac-transpl recipi